These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27581054)

  • 21. Bone mineral density and its correlation with clinical and laboratory factors in chronic peritoneal dialysis patients.
    Ersoy FF; Passadakis SP; Tam P; Memmos ED; Katopodis PK; Ozener C; Akçiçek F; Camsari T; Ateş K; Ataman R; Vlachojannis JG; Dombros AN; Utaş C; Akpolat T; Bozfakioğlu S; Wu G; Karayaylali I; Arinsoy T; Stathakis PC; Yavuz M; Tsakiris JD; Dimitriades CA; Yilmaz ME; Gültekin M; Karayalçin B; Yardimsever M; Oreopoulos DG
    J Bone Miner Metab; 2006; 24(1):79-86. PubMed ID: 16369903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of cyclosporine A on bone density in female rheumatoid arthritis patients: results from a multicenter, cross-sectional study.
    Mazzantini M; Di Munno O; Sinigaglia L; Bianchi G; Rossini M; Mela Q; Del Puente A; Frediani B; Cantatore F; Adami S
    Clin Exp Rheumatol; 2007; 25(5):709-15. PubMed ID: 18078618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and characteristics of bone disease in cirrhotic patients under evaluation for liver transplantation.
    Alcalde Vargas A; Pascasio Acevedo JM; Gutiérrez Domingo I; García Jiménez R; Sousa Martín JM; Ferrer Ríos MT; Sayago Mota M; Giráldez Gallego A; Gómez Bravo MA
    Transplant Proc; 2012; 44(6):1496-8. PubMed ID: 22841194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab.
    Miyazawa Y; Sekine Y; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
    Anticancer Res; 2017 Jul; 37(7):3667-3671. PubMed ID: 28668858
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment.
    Ferrari S; Libanati C; Lin CJF; Brown JP; Cosman F; Czerwiński E; de Gregόrio LH; Malouf-Sierra J; Reginster JY; Wang A; Wagman RB; Lewiecki EM
    J Bone Miner Res; 2019 Jun; 34(6):1033-1040. PubMed ID: 30919997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial.
    Langdahl BL; Teglbjærg CS; Ho PR; Chapurlat R; Czerwinski E; Kendler DL; Reginster JY; Kivitz A; Lewiecki EM; Miller PD; Bolognese MA; McClung MR; Bone HG; Ljunggren Ö; Abrahamsen B; Gruntmanis U; Yang YC; Wagman RB; Mirza F; Siddhanti S; Orwoll E
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1335-42. PubMed ID: 25607608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relation between body mass index and bone mineral density among haemodialysis patients with chronic kidney disease.
    Castillo RF; de la Rosa RJ
    J Ren Care; 2009 Mar; 35 Suppl 1():57-64. PubMed ID: 19222733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study.
    Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Fan M; Kim D
    Breast Cancer Res Treat; 2009 Nov; 118(1):81-7. PubMed ID: 19308727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Efficacy of Denosumab in Patients With Rheumatoid Arthritis: A Systematic Review and Pooled Analysis of Randomized or Matched Data.
    Hu Q; Zhong X; Tian H; Liao P
    Front Immunol; 2021; 12():799575. PubMed ID: 35069583
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone mineral density and vertebral fractures in men.
    Legrand E; Chappard D; Pascaretti C; Duquenne M; Rondeau C; Simon Y; Rohmer V; Basle MF; Audran M
    Osteoporos Int; 1999; 10(4):265-70. PubMed ID: 10692973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual energy X-ray absorptiometry of the calcaneus: comparison with other techniques to assess bone density and value in predicting risk of spine fracture.
    Yamada M; Ito M; Hayashi K; Ohki M; Nakamura T
    AJR Am J Roentgenol; 1994 Dec; 163(6):1435-40. PubMed ID: 7992742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Observations following discontinuation of long-term denosumab therapy.
    McClung MR; Wagman RB; Miller PD; Wang A; Lewiecki EM
    Osteoporos Int; 2017 May; 28(5):1723-1732. PubMed ID: 28144701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
    Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
    Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Saridakis ZG; Digkas D; Bisbinas I; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Osteoporos Int; 2015 Oct; 26(10):2521-7. PubMed ID: 25990355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trabecular bone score in kidney transplant recipients.
    Naylor KL; Lix LM; Hans D; Garg AX; Rush DN; Hodsman AB; Leslie WD
    Osteoporos Int; 2016 Mar; 27(3):1115-1121. PubMed ID: 26608055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does the combination of quantitative ultrasound and dual-energy X-ray absorptiometry improve fracture discrimination?
    Frost ML; Blake GM; Fogelman I
    Osteoporos Int; 2001; 12(6):471-7. PubMed ID: 11446563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bone mineral density and biochemical markers of bone metabolism in predialysis patients with chronic kidney disease.
    Fidan N; Inci A; Coban M; Ulman C; Kursat S
    J Investig Med; 2016 Apr; 64(4):861-6. PubMed ID: 26969749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Singh Index and Osteoporosis Self-Assessment Tool for Asians as risk assessment tools of hip fracture in patients with type 2 diabetes mellitus.
    Liu Z; Gao H; Bai X; Zhao L; Li Y; Wang B
    J Orthop Surg Res; 2017 Mar; 12(1):37. PubMed ID: 28253896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.